Restorbio Inc Headquarters

Looking for information about Restorbio Inc Headquarters? The links below have collected all the necessary data.

ResTORbio Company Profile - Office Locations, Competitors ...

https://craft.co/restorbio

Sep 18, 2020 · ResTORbio has 7 employees. Who are ResTORbio competitors? Competitors of ResTORbio include Zhaoke Ophthalmology Pharmaceutical, JUVIC and ZeCardio Therapeutics. Where is ResTORbio headquarters? ResTORbio headquarters is located at 500 Boylston St 13th floor, Boston. Where are ResTORbio offices? ResTORbio has an office in Boston.Employees: 7

resTORbio - Crunchbase Company Profile & Funding

https://www.crunchbase.com/organization/restorbio

resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.The Company develops medicines and therapies to treat aging-related diseases and conditions such as cancer, heart disease, neurodegenerative diseases, and diabetes mellitus.Founded: 2016

resTORbio Company Profile: Acquisition & Investors PitchBook

https://pitchbook.com/profiles/company/179079-85

Description. resTORbio Inc is a clinical-stage biopharmaceutical company. It mainly focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company focuses on the mechanistic target of rapamycin (mTOR) pathway which regulates aging, and specifically on selective inhibition of the ...

Adicet Announces Completion of Merger with resTORbio ...

https://investor.adicetbio.com/news-releases/news-release-details/adicet-announces-completion-merger-restorbio

Sep 15, 2020 · MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc. (previously trading on Nasdaq under the symbol ...

Adicet Announces Completion of Merger with resTORbio

https://www.globenewswire.com/news-release/2020/09/15/2093777/0/en/Adicet-Announces-Completion-of-Merger-with-resTORbio.html

Sep 15, 2020 · September 15, 2020 08:55 ET Source: resTORbio, Inc. - Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - …Author: Restorbio, Inc.

Biopharma startup ResTORbio stock plummets on late-stage ...

https://www.bizjournals.com/boston/news/2019/11/15/restorbio-stock-plummets-on-late-stage-drug.html

Nov 15, 2019 · The startup’s stock price dropped close to 85 percent on the news, trading around $1.23 per share as of 2:45 p.m. The drug, called RTB101, is resTORbio’s only clinical stage drug candidate.